|
|
Article: Callisto Announces Appointment of Dr. Arthur Sytkowski as Clinical Trial Advisor and Medical Safety Monitor; Veteran Scientist and Harvard Professor to Guide Callisto's Expanding Clinical Programs for Atiprimod and L-Annamycin.
- Article from:
- Business Wire
- Article date:
- March 9, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has announced that Dr. Arthur Sytkowski, Associate Professor of Medicine at Harvard University, has agreed to serve as Callisto's Clinical Trial Advisor and Medical Safety Monitor. Dr. Sytkowski will advise on Callisto's expanding clinical programs to develop its anticancer drugs Atiprimod and L-Annamycin.
Dr. Sytkowski brings to Callisto considerable experience with clinical development of cancer drugs from Phase I through Phase III, which he has gained through experience with a number of leading ...